Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Peppermint Oil→

Peppermint Oil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8006-90-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Volatile essential oil (Mentha × piperita)gastrointestinal antispasmodic
Mechanism of action
The principal gastrointestinal pharmacological effect is a dose-related antispasmodic action on smooth muscle. Menthol interferes with calcium movement across smooth-muscle cell membranes, reducing gastrointestinal spasm; carminative and antifoaming effects may also contribute.
Indications / reported uses
  • Symptomatic relief of mild gastrointestinal complaints associated with flatulence and abdominal pain, including functional bowel disorders such as irritable bowel syndrome, for appropriate oral enteric-coated preparations; topical preparations have different uses

Sources: EMA herbal monograph — Mentha × piperita L., aetheroleum (peppermint oil) · EMA herbal medicinal products information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Peppermint Oil Environmental Risk Assessment (ERA) (the Peppermint Oil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.